Development of antagonists of the platelet-derived growth factor receptor family

Oncology Spectrums

Volumn 2, Issue 8, 2001, Pages 550-556

  Giese, N A ^a   Lokker, N A ^a   Yu, J C ^a   Matsuno, K ^a   Ichimura, M ^a   Oda, S ^a   Scarborough, R ^a   Pandey, A ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR RECEPTOR; CT 38739; CT 50120; CT 52923; CT 56040; CT 56066; EPIDERMAL GROWTH FACTOR RECEPTOR; FLT3 LIGAND; HYBRID PROTEIN; KN 1022; KN 734; MACROLIDE; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZOLE DERIVATIVE; QUINAZOLINE DERIVATIVE; STAUROSPORINE; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSAY; AUTOCRINE EFFECT; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOPLASM; DISEASE COURSE; DISEASE MODEL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME INHIBITION; FIBROBLAST; GENE MUTATION; IC 50; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER;

EID: 0034794181     PISSN: 15328554     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Growth factor signaling by receptor tyrosine kinases
2. Oncogenic kinase signalling
3. Platelet-derived growth factor receptor signals
4. Dimerization of cell surface receptors in signal transduction
5. Transmembrane signaling by receptor oligomerization
6. Cell signaling by receptor tyrosine kinases
7. Novel mechanisms of RTK signal generation
8. Clinical trials of Herceptin(R) (trastuzumab)
9. First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer a preliminary report
10. Platelet-derived growth factor/sis in normal and neoplastic cell growth
11. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop
12. Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor
13. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors
14. The autocrine loop of TGF-alpha/EGFR and brain tumors
15. Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus
16. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
17. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing C-KIT (CD117)
18. STI571, an active drug in metastatic gastro intestinal stromal tumors (GIST), an EORTC phase I study
19. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
20. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
21. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorders
22. Mastocytosis: Molecular mechanisms and clinical disease heterogeneity
23. C-kit mutations in core binding factor leukemias
24. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
25. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies: A study on a large series of patients and cell lines
26. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia
27. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene
28. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
29. FMS mutations in myelodysplastic, leukemic, and normal subjects
30. Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia
31. A C-terminal FMS mutation in a patient with B-cell malignancy
32. Biological consequences of a point mutation at codon 969 of the FMS gene
33. Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus
34. Transformation by v-sis occurs by an internal autoactivation mechanism
35. Platelet-derived growth factor: Mechanism of action and possible in vivo function
36. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation
37. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways
38. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2)
39. Functional importance of platelet-derived growth factor (PDGF) receptor extracellular immunoglobulin-like domains: Identification of PDGF binding site and neutralizing monoclonal antibodies
40. Efficacy of a novel selective PDGFR antagonist CT52923 on cellular proliferation, migration and suppression of neointima following vascular injury
41. Selective inhibitor of PDGFR receptor phosphorylation: Synthesis, structure activity relationships and biological effects
42. Tyrosine kinase inhibition: An approach to drug development
43. The epidermal growth factor receptor and its inhibition in cancer therapy
44. Tyrosine kinase inhibitors, 17: Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido
45. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase
46. Preclinical profile of PKI166: A novel and potent EGFR tyrosine kinase inhibitor for clinical development
47. Diverse signaling pathways activated by growth factor receptors induce broadly overlapping, rather than independent, sets of genes
48. TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: A common mechanism for transformation by tyrosine kinase fusion proteins
49. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase